Skip to content
TrialScanner

NCT03472040

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Phase 2/Phase 3CompletedBCRXLead

Registry record

Lead sponsor
BioCryst Pharmaceuticals
Conditions
Hereditary Angioedema; HAE; Prophylaxis
Primary completion
Apr 27, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03472040 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.